日本成年人中肥胖和血液恶性瘤死亡率之间的关联:日本协作队列研究
Hana Wakasa1, Satoshi Sunohara1,2, Takashi Kimura3
1Department of Public Health, Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
PloS one
|October 30, 2025
概括
在日本成年人中,肥胖显著增加了因多发性骨髓瘤和白血病,特别是骨髓性白血病的死亡风险. 这突显了肥胖症作为这些血液性恶性瘤的关键可修改的危险因素.
科学领域:
- 流行病学 流行病学
- 在瘤学瘤学.
- 公共卫生 公共卫生
背景情况:
- 肥胖是一个全球性健康问题,与癌症死亡率的增加有关.
- 关于肥胖对亚洲人群,特别是日本成年人血液恶性瘤死亡率的影响的数据有限.
研究的目的:
- 调查日本成年人肥胖和血液恶性瘤死亡率之间的关联.
- 分析特定的血液性恶性瘤类型,包括淋巴瘤,多发性骨髓瘤和白血病.
主要方法:
- 利用了来自日本协作队列 (JACC) 研究的97,073名参与者的数据,平均随访时间为17年.
- 计算了身体质量指数 (BMI),并将参与者分为体重不足,体重正常,超重和肥胖的组.
- 采用考克斯的比例危险模型来估计死亡率的因果特定危险比率 (HRs),调整各种因素.
主要成果:
- 肥胖 (BMI ≥30.0 kg/m2) 与所有血液恶性瘤 (HR:1.78),多发性髓瘤 (HR:2.75) 和白血病 (HR:2.47) 的死亡风险显著增加有关.
- 在肥胖和髓性白血病死亡率 (HR:3.89) 之间发现了特别强烈的联系.
- 没有观察到BMI和淋巴瘤死亡率之间的显著联系.
结论:
- 肥胖与日本成年人多发性骨髓瘤和白血病,特别是骨髓性白血病的死亡率增加有显著关联.
- 研究结果强调,肥胖是这一群体中特定血液性恶性瘤的关键可修改的危险因素.
相关概念视频
01:24Obesity
1.1K
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.1K
01:21Cancer Survival Analysis
639
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
639
01:29Bias in Epidemiological Studies
1.3K
Biases can arise at various stages of research, from study design and data collection to analysis and interpretation. Recognizing and addressing these biases is essential to ensure the validity and reliability of epidemiological findings.Broadly speaking, biases in epidemiology fall into three main categories: selection bias, information bias, and confounding. A more detailed description of possible biases is:
1.3K
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
233
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
233
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
164
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
164
01:21Drug Dosing: Obese Patients
216
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
216